Brian Mehling

About Brian Mehling

Brian Mehling M.D. is the founder and Chief Medical Officer of Blue Horizon International, LLC. Dr. Mehling is also a world-renowned orthopedic trauma surgeon whose mainstay of practice is in the greater New York City metropolitan area. Dr. Mehling completed his residency in Orthopedic Surgery at The St. Joseph’s Hospital, Patterson, New Jersey and performed his fellowship in sports medicine at Graduate Hospital, Philadelphia, Pennsylvania. He is an alumnus of The Ohio State University and also holds a Master’s of Science Degree in Biochemistry. Dr. Mehling first conceived the Blue Horizon International Hospital concept while appraising differences in medical healthcare standards throughout Asia and the Middle East. Dr. Mehling recognized the truly significant need for universally high quality benchmarks in foreign nations and surmised that bringing the world’s best physicians to regions abroad would advance the standard of healthcare world-wide. In addition, American Nationals traveling in foreign lands would be able to receive the same quality of healthcare they have grown to expect at home. In association with Blue Horizon International, Blue Horizon’s Stem Cell Therapy Program provides an opportunity for the global community to participate in groundbreaking research while receiving stem cell therapy via state-of-the-art procedures provided in today’s western hospital safety conditions.Dr. Mehling is also a documentary film producer, debuting the film Tiny Tears at the prestigious Cannes Film Festival as well as a philanthropist, supporting many worthy causes dedicated to providing healthcare to children in impoverished areas.

Experience

1. Chief Medical Officer

   Blue Horizon International

   Mar 2015 — Present · New York, NY, US

   BHI Therapeutic Sciences was formed with the mission to advance stem cell therapy in full regulatory conformance and in conjunction with the scientific community, while making stem cell therapy available to those suffering from degenerative diseases such as Parkinson\'s and Alzheimer\'s as well as debilitating conditions resulting from stroke, neurological damage, and spinal cord injuries. Headquartered in New York, BHI researchers and investigators are conducting safety and efficacy studies on intravenously administered cord blood stem cells. With three American approved Institutional Review Board approved protocols, we are collecting and analyzing our data and have been published in three journals. Our mission is three-pronged and includes philanthropy through our charitable foundation, research and development, and clinical application. BHI Therapeutic Sciences has assembled a team of industry leading experts to deliver high-quality care, including highly skilled scientists and physicians.

Education

• The Ohio State University

  Master of Science (MS), Biochemistry

  1990 — 1994

• Wright State University Boonshoft School of Medicine

  Doctor of Medicine (MD), Medicine

  1991 — 1996

• The Ohio State University

  Bachelor of Arts (BA), Biochemistry

  1984 — 1989

• Seton Hall University

  Doctor of Philosophy (PhD) Candidate, Chemistry

  1997 — 2011

Skills

• Healthcare
• Marketing Strategy
• New Business Development
• Business Strategy
• Entrepreneurship
• Social Media
• Marketing
• Leadership
• Management
• Strategic Planning